What is the main business of Valueadd Pharma?

The main business activity of Valueadd Pharma focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on March 3, 2017.

Where is the headquarters located?

The headquarters is located at: ul. Domaniewska 47, 02-672 Warszawa.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of $1,755 in 2025, which is an increase of 8.5% compared to 2024.

Yes, the company recorded a net profit of $965 in 2025, meaning the company increased its profit by 16.6%.

What is the largest operating cost?

The largest operating cost category falls under external services. This category amounted to $789 in 2025, representing 100% of all operating expenses.

Valueadd Pharmasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2017-03-03

Share capital

5 000,00 PLN

Registered address

ul. Domaniewska 47/10, 02-672 Warszawa, Poland

Financials

Revenue history

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 247 days late).

202502/04/2026
202419/03/2025
202319/03/2025
202226/04/2023
202127/04/2022
202029/04/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.75kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD 965.33MedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 789.39MedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 2.22kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Deepak Kumar Murpani – President of the Management Board

Manner of representation

The President of the Management Board is authorised to independently make declarations of will on behalf of the company. If the management board is a multi-member management board, for the remaining members of the management board to make declarations of will on behalf of the company, joint action of two members of the management board is required.

Ownership

Owner	Shares	Share value	Stake
Deepak Kumar Murpaniage 54	90	$1,215.56	90%
Kalpana Deepak Murpani	10	$135.06	10%

Deepak Kumar Murpani and Kalpana Deepak Murpani hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person	Rights

Subsidiaries

	Name	Stake
	Valueadd Pharma (By Dr. Murpani)sp. k.	–

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Bioselsp. z o.o.	$19,100.32	selol.pl
Omnisepticasp. z o.o.	$3,475.29	omniseptica.com
Wavex Energysp. z o.o.	$142.33	wavexenergy.com